Mersana Therapeutics, Inc. (MRSN)
NASDAQ: MRSN · Real-Time Price · USD
7.21
+0.04 (0.56%)
At close: Sep 16, 2025, 4:00 PM EDT
7.27
+0.06 (0.83%)
After-hours: Sep 16, 2025, 6:28 PM EDT
Mersana Therapeutics Stock Forecast
Stock Price Forecast
The 2 analysts that cover Mersana Therapeutics stock have a consensus rating of "Strong Buy" and an average price target of $33, which forecasts a 357.70% increase in the stock price over the next year. The lowest target is $30 and the highest is $36.
Price Target: $33 (+357.70%)
Analyst Consensus: Strong Buy
* Price targets were last updated on Aug 14, 2025.
Analyst Ratings
The average analyst rating for Mersana Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 | Sep '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 2 |
| Buy | 2 | 1 | 1 | 1 | 1 | 1 |
| Hold | 2 | 1 | 1 | 1 | 1 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 5 | 5 | 5 | 5 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Truist Securities | Truist Securities | Strong Buy Maintains $250 → $36 | Strong Buy | Maintains | $250 → $36 | +399.31% | Aug 14, 2025 |
| Guggenheim | Guggenheim | Strong Buy Maintains $125 → $30 | Strong Buy | Maintains | $125 → $30 | +316.09% | Aug 14, 2025 |
| Truist Securities | Truist Securities | Strong Buy Maintains $225 → $250 | Strong Buy | Maintains | $225 → $250 | +3,367.41% | May 16, 2025 |
| Guggenheim | Guggenheim | Strong Buy Reiterates $125 | Strong Buy | Reiterates | $125 | +1,633.70% | May 16, 2025 |
| William Blair | William Blair | Buy Initiates n/a | Buy | Initiates | n/a | n/a | Feb 6, 2025 |
Financial Forecast
Revenue This Year
25.80M
from 40.50M
Decreased by -36.29%
Revenue Next Year
20.09M
from 25.80M
Decreased by -22.12%
EPS This Year
-13.60
from -14.12
EPS Next Year
-10.97
from -13.60
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 37.8M | 44.9M | |||
| Avg | 25.8M | 20.1M | |||
| Low | 14.7M | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -6.7% | 74.2% | |||
| Avg | -36.3% | -22.1% | |||
| Low | -63.7% | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|
| High | -7.09 | -3.41 | ||
| Avg | -13.60 | -10.97 | ||
| Low | -15.97 | -16.68 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|
| High | - | - | ||
| Avg | - | - | ||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.